DJIA 17,778.15 421.28 2.43%
NASDAQ 4,748.40 104.08 2.24%
S&P 500 2,061.23 48.34 2.40%
market minute promo

BioTime, Inc. (NYSEMKT: BTX)

3.46 -0.03 (-0.86%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

BTX $3.46 -0.86%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.42
Previous Close $3.49
Daily Range $3.31 - $3.46
52-Week Range $2.21 - $4.14
Market Cap $287.6M
P/E Ratio -4.53
Dividend (Yield) $0.00 (0.0%)
Volume 136,667
Average Daily Volume 176,644
Current FY EPS $0.00

Sector

Healthcare

Industry

Drugs

BioTime, Inc. (BTX) Description

BioTime Inc. is engaged in the business of developing blood plasma volume expanders and related products and stem cell related products and technology for diagnostic therapeutic and research use. Website: http://www.biotimeinc.com/

News & Commentary

Is Geron Finally Onto Something?

Here's why biotech Geron is a prime buyout target.

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urin

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic

UPDATE: BioTime Appoints Angus C. Russell To Bd Of Directors

Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options

BioTime Harnesses Geron's Stem Cell Technology And Its Founder; Is That Enough To Survive The Biotec

BioTime Harnesses Geron's Stem Cell Technology And Its Founder; Is That Enough To Survive The Biotech Revolution?

A Timely Interview With BioTime's CEO And His Chief Commercial Officer

UPDATE: BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia In Europe

BioTime: Recent News Hints At Positive Developments

BioTime Is Right On Time: Files IND For AMD

BioTime Subsidiary, Asterias Biotherapeutics, And Cancer Research UK And Cancer Research Technology

BioTime Subsidiary, Asterias Biotherapeutics, And Cancer Research UK And Cancer Research Technology Partner For Clinical Trial Of Immunotherapy Vaccine For Lung Cancer

BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog

See More BTX News...

BTX's Top Competitors

BTX $3.46 (-0.86%)
Current stock: BTX
AMGN $168.48 (3.06%)
Current stock: AMGN
GILD $105.54 (3.07%)
Current stock: GILD
BIIB $353.70 (6.25%)
Current stock: BIIB